Subscribe To
VRAY / ViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022
VRAY News
By InvestorPlace
July 17, 2023
Why Is ViewRay (VRAY) Stock Down 69% Today?
ViewRay (NASDAQ: VRAY ) stock is falling hard on Monday after the MRI company announced its voluntary Chapter 11 bankruptcy filing! According to the c more_horizontal
By Zacks Investment Research
May 10, 2023
ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates
ViewRay (VRAY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.1 more_horizontal
By Seeking Alpha
April 13, 2023
ViewRay: Shares Crater As Company Warns Of Slower Growth, Higher Cash Burn
Magnetic resonance imaging-guided radiation therapy system provider ViewRay, Inc. has shocked investors with a severe revenue and cash flow warning. more_horizontal
By PRNewsWire
April 12, 2023
ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023
DENVER , April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13 more_horizontal
By Seeking Alpha
February 27, 2023
ViewRay, Inc. (VRAY) Q4 2022 Earnings Call Transcript
ViewRay, Inc. (NASDAQ:VRAY ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Matt Harrison - Director of IR Scott D more_horizontal
By Zacks Investment Research
February 27, 2023
ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates
ViewRay (VRAY) delivered earnings and revenue surprises of 6.25% and 0.71%, respectively, for the quarter ended December 2022. Do the numbers hold clu more_horizontal
By Seeking Alpha
February 12, 2023
ViewRay: Sales, Order Momentum Ratcheting Higher
ViewRay has continued growth in order momentum. Its stock price has moved sideways into the new year, adding another attractive entry point. more_horizontal
By Seeking Alpha
November 24, 2022
ViewRay: Revise Thesis To Buy, Multiple Upside Targets In Place
Revised FY22 revenue guidance with management more confident on the lower end of range. Backlog continues to grow, ending 26% higher to $350mm for the more_horizontal